症狀檢驗報告

睡眠呼吸中止 (OSA)

英文名稱:Sleep Apnea

共有幾筆評級
1 筆
資料日期
2026-06-09

檢驗結果

逐筆明細

A中度證據實證評級速查

保健成分 × 適應症

Tirzepatide (Mounjaro / Zepbound / 穆桂諾) × 睡眠呼吸中止 (OSA)

72
分(滿分 100)

白話說:中度證據,有一定的支持。

發布狀態:可參考,但附帶但書

部分研究有廠商利益台灣有獨立規範
各國衛生機關怎麼說
  • 第三方營養資料庫(國際)
    展開原文引用
    「Tirzepatide is a once-weekly injectable dual GIP/GLP-1 receptor agonist (Mounjaro for type 2 diabetes, Zepbound for obesity) developed by Eli Lilly, FDA-approved 2022/2023.」
  • 美國 FDA 態度:支持
    展開原文引用
    「MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. WARNING: RISK OF THYROID C-CELL TUMORS — Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell …」
  • 歐盟 EFSA 態度:支持
    展開原文引用
    「Mounjaro received a marketing authorisation valid throughout the EU on 15 September 2022. The active substance in Mounjaro, tirzepatide, acts in the same way as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Mounjaro is a prescription-only medicine indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct…」

評級由多源健康證據引擎彙整(FDA/EFSA/NHS/TFDA/WHO/PubMed/NIH ODS 等多個官方與權威來源)。 產製日期 2026-06-09 · 版本 v5。本評級僅供衛教參考,不取代醫師診斷與處方。 · 查看此成分的完整評級 · 證據資料庫原始頁面